Logo Image
Opinion|Videos|October 2, 2024

Navigating Toxicity: Comparing Third-Line mCRC Therapies

Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.

Episodes in this series

Video content above is prompted by the following:

  • How do the toxicity profiles differ with FTD/TPI plus bevacizumab, as compared with regorafenib or fruquintinib, and how might these different toxicity profiles be leveraged when making treatment selections?
  • What are some key, practical strategies you use to manage treatment-related toxicities with these third-line therapies?

Related Content